Phase-three trial results of ViiV Healthcare’s new HIV drug in adual-drug regimen proved to be successful. The latest progress of ViiV Healthcare—a unit of GlaxoSmithKline PLC—can boost the company’s chances of hitting their bets on their ability to modify the three-drug combinations that try to treat AIDS.
The UK-based pharmaceutical giant claimed that its HIV pill dolutegravir plus Johnson & Johnson’s rilpivirine repress the virus with the same effectiveness as conventional three- or four-drug combinations when two identical yearlong trials were conducted involving around 500 patients.
ViiV Healthcare chief Dominique Limet stated that the two-drug combination is scheduled to be submitted next year to regulators. Both of these medicines are already sold as individual components in three-drug combinations or more.
If approved by the regulation, this will help in the establishment of dolutegravir as the base of simpler two-drug regimens for treating HIV.
HIV is the virus that causes AIDS. The emergence of two-drug regimens will upend the long-standing usage of at least three antiretroviral medicines to manage the virus. The three-drug combinations changed AIDS from a terminal disease to an illness that can be controlled for the long-term.
The development could also aid Glaxo in strengthening its grip in the HIV business against arch nemesis Gilead Sciences Inc. which is currently developing a drug that would make its already-dominant three-drug regimen more powerful still.
But analysts do not have their full bets on the new drug as Gilead can still have the upper hand in the long run when it comes to drugs that seek to suppress the adverse effects of HIV.
Interested in trading binary options. Don’t go anywhere else, try Options12.com.Options12.com brings your money back to you, the difference? Options12 prioritizes each client in maximizing his/her trading potential.
Financial trouble? Let Exo Capital Markets manage your funds accordingly. Exo Capital Markets strives to become the leading financial services firm by offering its clients with the most modern solutions in the industry.